NWM
NBIX icon

Northwest Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Northwest Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Sell
1,879
-584
-24% -$86.6K 0.04% 193
2026
Q1 		$324K Buy
2,463
+688
+39% +$91.3K 0.05% 173
2025
Q4 		$252K Buy
+1,775
New +$257K 0.04% 206

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
AS
Aware Super Sydney, Australia $7.06B AUM
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Retirement Systems of Alabama
Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Northwest Wealth Management's NBIX Position: Q2 2026 in Review

Northwest Wealth Management reduced its Neurocrine Biosciences (NBIX) stake by 24% in Q2 2026, selling an estimated $86.6K and leaving 1,879 shares worth $317K. The position accounts for 0.04% of the portfolio, ranked #193.

Northwest Wealth Management first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. The position peaked at $324K in Q1 2026. 239 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Northwest Wealth Management held 1,879 shares of Neurocrine Biosciences worth $317K as of Q2 2026.
  • Northwest Wealth Management sold 584 Neurocrine Biosciences shares in Q2 2026, an estimated $86.6K.
  • Neurocrine Biosciences made up 0.04% of Northwest Wealth Management's portfolio in Q2 2026, its #193 holding.
  • Northwest Wealth Management first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Northwest Wealth Management's Neurocrine Biosciences position peaked at $324K in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Northwest Wealth Management's 13F filing for Q2 2026, filed 13 Jul 2026.